|
Etanercept for Non-Infectious Lung Injury Following Bone Marrow Transplantation Clinical Trials Facts presented on Clinical Trials Search isn't designed to be a substitute for proven healthcare advice, calls or treatment using a real mD. We aren't mDs. Always confer with your physician on Etanercept for Non-Infectious Lung Injury Following Bone Marrow Transplantation conditions. Clinical Trials Search.org is a website dedicated to listing clinical research studies in human subjects. Etanercept for Non-Infectious Lung Injury Following Bone Marrow Transplantation Clinical research trials and Etanercept for Non-Infectious Lung Injury Following Bone Marrow Transplantation healthcare trials happen in a lot of of localities across the United States of America. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally measure the potency of new drugs. The aim of the studies / undertakings is to answer particular human medical questions. Clinical trials are a popular manner for doctors, government agencies, and private sector corporations to discover remedies for all kinds of circumstances, such as Etanercept for Non-Infectious Lung Injury Following Bone Marrow Transplantation. Etanercept for Non-Infectious Lung Injury Following Bone Marrow Transplantation Clinical Trials and other clinical trials allow volunteers to get healthcare treatment alternatives before they are available to the general public. Most times the participants receive treatment for without cost, and occasionally they are paid for their time. Sometimes there is a cost for a Etanercept for Non-Infectious Lung Injury Following Bone Marrow Transplantation clinical trial. Human subjects often receive the most effective healthcare possible for their Etanercept for Non-Infectious Lung Injury Following Bone Marrow Transplantation condition. Risks are a reality, nonetheless, and may include more or frequent dr. calls, healthcare hazards (perhaps life-threatening), and/or the treatment being ineffective. Trials are federally governed with rigorous guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "E" Clinical Trials Conditions > Etanercept for Non-Infectious Lung Injury Following Bone Marrow Transplantation  Etanercept for Non-Infectious Lung Injury Following Bone Marrow Transplantation
Etanercept for Non-Infectious Lung Injury Following Bone Marrow Transplantation
For Condition: Pneumonia,Bronchiolitis Obliterans,Respiratory Distress Syndrome, Adult
Status: Recruiting
Sponsor(s): FDA Office of Orphan Products Development ,
Synopsis: The purpose of this study is to determine the effects of etanercept, and define the toxicity, when administered to patients with acute non-infectious lung injury (idiopathic pneumonia syndrome, IPS) and with subacute pulmonary dysfunction after allogeneic stem cell transplantation.
Details: Over the last 2 decades, allogeneic bone marrow transplantation (BMT) has emerged as an important treatment option for a number of malignant and non-malignant disorders. Unfortunately, pulmonary dysfunction remains a frequent and severe complication of allogeneic BMT. One of the main chemicals felt to cause lung damage is Tumor Necrosis Factor (TNF). Etanercept is an experimental drug that attempts to block TNF lung damage. Patients will undergo blood tests, x-rays, and a bronchoscopy with broncho-alveolar lavage prior to treatment with etanercept to check for infection. If no infection is evident after 24 hours, the etanercept will be started and administered twice weekly for 4 weeks by subcutaneous injection. There will be weekly blood tests and bronchoscopy after the last drug dose.
Eligibility:
Study Type: Interventional, Treatment, Non-Randomized, Open Label, Uncontrolled, Safety/Efficacy Study
Minimum Age/Maximum Age: 12 Months/
Genders: Both
Protocol Entry Criteria: Inclusion criteria: - Diagnosis of acute idiopathic pneumonia syndrome (IPS) or sub-acute lung injury - At least 1 year of age for IPS stratum - At least 6 years of age for sub-acute lung injury stratum and able to perform formal pulmonary function testing - At least 14 days since prior treatment with an investigational drug for graft-versus-host disease - Previously treated with allogeneic stem cell or bone marrow transplantation for primary disease Exclusion criteria: - Documented evidence of active systemic or pulmonary infection - Cardiogenic failure as cause of pulmonary dysfunction - Known hypersensitivity to etanercept - Currently receiving dialysis - Currently receiving inotropic medications except dopamine - Pregnant or nursing
Total Enrollment: 15
Location and Contact Information:
Overall Study Official:
KennethCooke, Principal Investigator, University of Michigan, Ann Arbor, MI
University of Michigan *Recruiting*
Ann Arbor, Michigan, 48109
United States
Recruiting Terri Maxwell 734-764-7246
Additional Information:
Study ID Numbers: FD-R-2020-01; UMCC-0078;,FD-R-002020-01
Study Start Date: September 2001
Record last reviewed: November 2001
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00029328
Other Bronchiolitis Obliterans Studies:
1. A Safety and Efficacy Study of Hospitalized Patients with Community-Acquired Pneumonia and Sepsis
2. Interferon Gamma for Drug Resistant Tuberculosis
3. Arginine Treatment of Acute Chest Syndrome (Pneumonia) in Sickle Cell Disease Patients
4. Intravenous Tigecycline Versus Intravenous Levofloxacin To Treat Subjects Hospitalized With Community-Acquired Pneumonia
5. Etanercept for Non-Infectious Lung Injury Following Bone Marrow Transplantation
Related Studies:
Other Bronchiolitis Obliterans Clinical Trials
Other Michigan Clinical Trials
Other Ann Arbor Clinical Trials
Etanercept for Non-Infectious Lung Injury Following Bone Marrow Transplantation
|
|
|
|
|
|
|
|
